Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Abstract Text:

Jeffrey N Weitzel,Saundra S Buys,William H Sherman,AnnaMarie Daniels,Giske Ursin,John R Daniels,Deborah J MacDonald,Kathleen R Blazer,Malcolm C Pike,Darcy V Spicer,

PURPOSE: Women with a BRCA1 mutation (BRCA1(mut)) need risk reduction options beyond mastectomy and oophorectomy. We evaluated the efficacy, safety, and tolerability of hormonal chemoprevention with a gonadotropin-releasing hormone agonist (GnRHA) with low-dose add-back steroids in BRCA1(mut) carriers. EXPERIMENTAL DESIGN: The 12-month open label clinical trial used the GnRHA deslorelin, ultra-low-dose estradiol (E(2)), and replacement testosterone, administered via daily intranasal spray in premenopausal women with a BRCA1(mut), and intermittent oral medroxyprogesterone acetate. The end points included mammographic percent density, bone mineral density, endometrial hyperplasia, symptom inventory, and quality of life (Medical Outcomes SF-36 survey). RESULTS: Six of eight BRCA1(mut) women (mean age, 30.3 years; range, 25-36 years) completed the study. Mammographic percent density was significantly reduced at 12 months (median absolute mammographic percent density decrease, 8.3%; P = 0.043), representing a 29.2% median reduction in mammographic percent density. Bone mineral density remained within reference limits for all participants; there were no cases of atypical endometrial hyperplasia and menses resumed within a median of 67 days (range, 35-110 days) after last drug treatment day. The treatment was well tolerated; hypoestrogenic side effects were minimal and transient; and there were no significant changes in quality of life. CONCLUSIONS: The GnRHA deslorelin, with low-dose add-back steroids, was well tolerated and significantly decreased mammographic percent density in BRCA1(mut) carriers. This regimen may reduce breast cancer risk and improve the usefulness of mammographic surveillance by reducing density. This is the first demonstration, to our knowledge, of a direct reduction of mammographic densities in young BRCA1(mut) carriers.

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Publishing Authors By Initials

JN Weitzel,SS Buys,WH Sherman,A Daniels,G Ursin,JR Daniels,DJ MacDonald,KR Blazer,MC Pike,DV Spicer,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 654-8

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 15

MONTH: Jan

YEAR: 2007

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Information

Substance Name: Medroxyprogesterone 17-Acetate

Registry Number: 71-58-9

Grant and Affiliation Information for Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.

AFFILIATION: Department of Clinical Cancer Genetics, City of Hope Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA. jweitzel@coh.org

Country: United States

AGENCY: United States NCI

GRANT: U01 CA 79428

ACRONYM: CA

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers Related Publications

• A method of estimating streptomycin in serum and other body fluids by diffusion through agar enclosed in glass tubes.
• A set of callipers for anatomical measurements.
• ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD.
• An investigation of the effects of material anisotropy and heterogeneity on pulsed, laser-generated acoustic signals.
• Assessment and prevention of head motion during imaging of patients with attention deficit hyperactivity disorder.
• Coexistence of acid phosphatase and acid mucosubstance in the nucleoid of human blood platelet granules.
• Comparison of medium- and high-energy collimators for 131I-tositumomab dosimetry.
• DENTAL CLUES TO MYASTHENIA GRAVIS.
• Developmental trajectories of personal and collective self-concept among American Indian adolescents.
• Ductal stent and cavo-atrial sac occlusion in an adult with profound cyanosis after palliated cyanotic congenital heart disease.
• Effect of para-aminobenzoic acid on the in vivo oxidation of hemoglobin.
• Effects of propionibacteria and yeast culture fed to steers on nutrient intake and site and extent of digestion.
• Epidermoid carcinoma in sebaceous cysts.
• Gut reaction by heartless shrimps: experimental evidence for the role of the gut in generating circulation before cardiac ontogeny.
• Issues in using state hospital discharge data in injury control research and surveillance.
• Kinetics of colloidal templating using emulsion drop consolidation.
• Mental health and substance abuse services to parents of children involved with child welfare: a study of racial and ethnic differences for American Indian parents.
• Multidimensional NMR spectroscopy for protein characterization and assignment inside cells.
• ON THE FORMATION OF CLEAR SPACES IN CORNEAL NEBULAE.
• Ocean acidification disrupts induced defences in the intertidal gastropod Littorina littorea.
• PMA induces stabilization of oncostatin M mRNA in human lymphoma U937 cells.
• Paradoxical hyperfixation of HMPAO in cerebral infarction.
• Parathyroid imaging with 99m Tc-sestamibi.
• Pediatric restrictive cardiomyopathy associated with a mutation in beta-myosin heavy chain.
• Phylogenetic relationships within an endemic group of Malagasy 'assassin spiders' (Araneae, Archaeidae): ancestral character reconstruction, convergent evolution and biogeography.
• Random alcohol testing reduced alcohol-involved fatal crashes of drivers of large trucks.
• Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.
• SALIVARY DUCTS BLOCKED. SUBMANDIBULAR SWELLING CAUSED BY DENTURES.
• Thermal tolerance, acclimatory capacity and vulnerability to global climate change.
• Twist1 dimer selection regulates cranial suture patterning and fusion.